Depends on the partnering route taken as to what the funds from the upfront are used for. The way I understand it:
Option A = Out license to big pharma = sale of the AD214 asset with an upfront payment & contingent milestones = no further spend on AD214 for Adalta, can use the upfront to develop the pipeline of other drugs
Option B = JV Partner with Private equity = AD214 into SPV, JV partner pays Adalta for a portion of equity in SPV = in phase II either the costs are shared with the JV partner or the JV partner pays 100% (depending on the deal and how much equity is given away) with hope of selling for more (to big pharma) at some point
- Forums
- ASX - By Stock
- 1AD
- Ann: Positive AD-214 Phase I extension study results
Ann: Positive AD-214 Phase I extension study results, page-203
-
- There are more pages in this discussion • 60 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add 1AD (ASX) to my watchlist
(20min delay)
|
|||||
Last
2.6¢ |
Change
0.002(8.33%) |
Mkt cap ! $15.48M |
Open | High | Low | Value | Volume |
2.6¢ | 2.6¢ | 2.6¢ | $8.093K | 311.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 554539 | 2.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.6¢ | 400000 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 554539 | 0.022 |
2 | 1047615 | 0.021 |
4 | 626841 | 0.020 |
3 | 1108500 | 0.019 |
3 | 338053 | 0.018 |
Price($) | Vol. | No. |
---|---|---|
0.026 | 400000 | 2 |
0.027 | 217643 | 2 |
0.028 | 125208 | 3 |
0.029 | 3041 | 1 |
0.030 | 17697 | 1 |
Last trade - 11.36am 26/07/2024 (20 minute delay) ? |
Featured News
1AD (ASX) Chart |